tobramycin · TOBRAMYCIN 1200 mg/30mL · Injection, Powder, For Solution · Intravenous · Slate Run Pharmaceuticals, LLC
NDC 70436-0110-36 · 30 mL in 1 VIAL · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 3× that.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Slate Run Pharmaceuticals, LLC | TOBRAMYCIN 1200 mg/30mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "tobramycin — NDC 70436-0110-36," retrieved September 3, 2026, https://drugdashboards.com/drug/70436011036.
Free to cite with attribution — see how the data is put together.